| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adding extra dimensions in rectal cancer theory
|
Glynne-Jones, R.
|
|
|
28 |
2 |
p. 198-200
|
artikel
|
| 2 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
|
Paz-Ares, L.
|
|
|
28 |
2 |
p. 270-277
|
artikel
|
| 3 |
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|
Menzies, A.M.
|
|
|
28 |
2 |
p. 368-376
|
artikel
|
| 4 |
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
|
Martín, M.
|
|
|
28 |
2 |
p. 313-320
|
artikel
|
| 5 |
A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
|
Yoshioka, H.
|
|
|
28 |
2 |
p. 285-291
|
artikel
|
| 6 |
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer† † This study was previously presented as: an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3–6, 2011, Chicago, IL, USA, and at the 14th World conference on Lung Cancer, July 3–7, 2011, Amsterdam, Netherlands.
|
Belani, C.P.
|
|
|
28 |
2 |
p. 298-304
|
artikel
|
| 7 |
Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy
|
Hoadley, A.
|
|
|
28 |
2 |
p. 434-435
|
artikel
|
| 8 |
Atypical autoimmune adverse effects with checkpoint blockade therapies
|
Friedman, C.F.
|
|
|
28 |
2 |
p. 206-207
|
artikel
|
| 9 |
Better use of immune checkpoint inhibition: Treating higher risk patients and examining neurologic toxicity
|
Postow, M.A.
|
|
|
28 |
2 |
p. 204-205
|
artikel
|
| 10 |
Cancer risk among 21st century blood transfusion recipients
|
Yang, T.O.
|
|
|
28 |
2 |
p. 393-399
|
artikel
|
| 11 |
Causes of death among cancer patients
|
Zaorsky, N.G.
|
|
|
28 |
2 |
p. 400-407
|
artikel
|
| 12 |
Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
|
Makkouk, A.
|
|
|
28 |
2 |
p. 415-420
|
artikel
|
| 13 |
Controversies and consensus in the innovation access for cancer therapy in the European countries: on the subject of metastatic prostate cancer
|
Oudard, S.
|
|
|
28 |
2 |
p. 421-426
|
artikel
|
| 14 |
Defining research priorities without biases: what is the optimal process?
|
Dogan, S.
|
|
|
28 |
2 |
p. 195-196
|
artikel
|
| 15 |
Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case–Control Consortium (PanC4)
|
Pelucchi, C.
|
|
|
28 |
2 |
p. 408-414
|
artikel
|
| 16 |
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99
|
Pagani, O.
|
|
|
28 |
2 |
p. 305-312
|
artikel
|
| 17 |
Don’t forget the host: a potential role for germinal polymorphisms as markers for checkpoint inhibitors
|
Milano, G.
|
|
|
28 |
2 |
p. 435-436
|
artikel
|
| 18 |
Editorial board
|
|
|
|
28 |
2 |
p. ii-iii
|
artikel
|
| 19 |
Identification of a FGFR3-TACC3 fusion in esophageal cancer
|
Mizukami, T.
|
|
|
28 |
2 |
p. 437-438
|
artikel
|
| 20 |
Improving brain penetration of kinase inhibitors in lung cancer patients with oncogene dependency
|
Remon, J.
|
|
|
28 |
2 |
p. 196-198
|
artikel
|
| 21 |
Infection-related complications during treatment for childhood acute lymphoblastic leukemia
|
Inaba, H.
|
|
|
28 |
2 |
p. 386-392
|
artikel
|
| 22 |
Is the pursuit of a higher impact factor fully justified?
|
Milano, G.
|
|
|
28 |
2 |
p. 439-440
|
artikel
|
| 23 |
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
|
Stauder, R.
|
|
|
28 |
2 |
p. 218-227
|
artikel
|
| 24 |
Management of CLL in the elderly
|
Cuneo, A.
|
|
|
28 |
2 |
p. 200-204
|
artikel
|
| 25 |
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course
|
Boeck, S.
|
|
|
28 |
2 |
p. 438-439
|
artikel
|
| 26 |
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial
|
Patel, U.B.
|
|
|
28 |
2 |
p. 344-353
|
artikel
|
| 27 |
Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature
|
Spain, L.
|
|
|
28 |
2 |
p. 377-385
|
artikel
|
| 28 |
Oncology drug costs—the imaginary crisis?
|
Turck, R.
|
|
|
28 |
2 |
p. 427-431
|
artikel
|
| 29 |
Pembrolizumab induced severe sclerodermoid reaction
|
Shenoy, N.
|
|
|
28 |
2 |
p. 432-433
|
artikel
|
| 30 |
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
|
Evans, T.R.J.
|
|
|
28 |
2 |
p. 354-361
|
artikel
|
| 31 |
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers †
|
Yu, H.A.
|
|
|
28 |
2 |
p. 278-284
|
artikel
|
| 32 |
Reply to the letter to the editor ‘Is the pursuit of a higher impact factor fully justified?’
|
Soria, J.-C.
|
|
|
28 |
2 |
p. 440
|
artikel
|
| 33 |
Reply to ‘The potential and perils of observational studies’ by M. Buyse et al.
|
Delaloge, S.
|
|
|
28 |
2 |
p. 436-437
|
artikel
|
| 34 |
Research needs in breast cancer
|
Cardoso, F.
|
|
|
28 |
2 |
p. 208-217
|
artikel
|
| 35 |
Risk of second malignant neoplasms in women and girls with germ cell tumors
|
Liao, Z.
|
|
|
28 |
2 |
p. 329-332
|
artikel
|
| 36 |
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials †
|
Gyawali, B.
|
|
|
28 |
2 |
p. 246-253
|
artikel
|
| 37 |
Second primary malignancies in multiple myeloma: an overview and IMWG consensus
|
Musto, P.
|
|
|
28 |
2 |
p. 228-245
|
artikel
|
| 38 |
Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study
|
Faivre, S.
|
|
|
28 |
2 |
p. 339-343
|
artikel
|
| 39 |
Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours
|
Heidenreich, A.
|
|
|
28 |
2 |
p. 362-367
|
artikel
|
| 40 |
Table of Contents
|
|
|
|
28 |
2 |
p. iv-vi
|
artikel
|
| 41 |
Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
|
Morel, D.
|
|
|
28 |
2 |
p. 254-269
|
artikel
|
| 42 |
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast
|
Pruneri, G.
|
|
|
28 |
2 |
p. 321-328
|
artikel
|
| 43 |
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study
|
Mangili, G.
|
|
|
28 |
2 |
p. 333-338
|
artikel
|
| 44 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial
|
Lee, S.-H.
|
|
|
28 |
2 |
p. 292-297
|
artikel
|
| 45 |
Vasculitic neuropathy induced by pembrolizumab
|
Aya, F.
|
|
|
28 |
2 |
p. 433-434
|
artikel
|
Tijdschrift beschrijving